RCT

SPICE III

Early Sedation with Dexmedetomidine in Critically Ill Patients

NEJM, 2019 · Multinational open-label randomized trial across 65 ICUs (n=3904)

Clinical question

Does early sedation with dexmedetomidine as the primary sedative reduce 90-day mortality compared with standard sedation in mechanically ventilated ICU patients?

Population: Critically ill adults expected to receive mechanical ventilation for > 24 hours within 12 hours of intubation
Intervention: Dexmedetomidine as the primary sedative agent
Comparator: Usual care sedation (propofol, midazolam, or other sedatives)
Primary outcome: All-cause mortality at 90 days
Result: 90-day mortality was 29.1% in the dexmedetomidine group vs 29.1% in the usual-care group (difference 0.0 percentage points; 95% CI, -2.9 to 2.8; P=0.98). Dexmedetomidine often required supplemental sedatives and caused more bradycardia/hypotension-related adverse events; the trial did not establish a survival advantage.

What the trial found

An early dexmedetomidine-primary strategy did not reduce 90-day mortality compared with usual-care sedation; supplemental sedatives were frequently needed.

Current guideline position

The 2025 SCCM PADIS focused update conditionally suggests dexmedetomidine over propofol when light sedation and/or reducing delirium are the highest priorities; patient-specific adverse effects and A2B results still support individualized choice.

Clinical interpretation

Dexmedetomidine is a useful non-benzodiazepine sedative for selected light-sedation goals, but SPICE III does not justify calling it universally superior or outcome-improving.

Clinical Context & Relevant Topics (1)

Disease Reference

ICU Sedation, Analgesia, Delirium & Liberation

Analgesia-first sedation, light sedation targets, ABCDEF bundle, spontaneous breathing trials, and non-pharmacologic delirium mitigation.

View Topic Context →